general/pan tumour

Edit Answers
123456789101112131415161718
Across
  1. 5. Dose of LIBTAYO given to patients
  2. 6. Approves drug indications
  3. 8. Information resource that contains efficacy, safety, and usage information for LIBTAYO
  4. 11. Minutes of LIBTAYO adminstration (single dose)
  5. 12. The immune response restored by LIBTAYO
  6. 13. Immune function inhibited by LIBTAYO
  7. 15. Profile in which adverse reactions are reported
  8. 16. Generates fully human therapeutic antibodies, including LIBTAYO
  9. 17. Method to confirm objective response rate (ORR)
  10. 18. First line immune response
Down
  1. 1. Statistical method often used in evaluating PFS
  2. 2. Tumor staging criteria
  3. 3. Objective response rate. Duration of Response. Complete response rate. Safety and tolerability.
  4. 4. Number of approved FDA indications for LIBTAYO
  5. 7. LIBTAYO biologic
  6. 9. LIBTAYO ________ enhances patient access to LIBTAYO
  7. 10. Criteria used to select patients for clinical trials
  8. 11. Expresses programmed death-receptor 1 (PD-1)
  9. 14. Administration method of LIBTAYO